F
Frederick R. Ahmann
Researcher at University of Arizona
Publications - 63
Citations - 4105
Frederick R. Ahmann is an academic researcher from University of Arizona. The author has contributed to research in topics: Prostate cancer & Prostate-specific antigen. The author has an hindex of 26, co-authored 63 publications receiving 4020 citations. Previous affiliations of Frederick R. Ahmann include Veterans Health Administration & United States Department of Veterans Affairs.
Papers
More filters
Journal ArticleDOI
Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.
William J. Catalona,Jerome P. Richie,Frederick R. Ahmann,M'Liss A. Hudson,Peter T. Scardino,Robert C. Flanigan,Jean B. deKernion,Timothy L. Ratliff,Louis R. Kavoussi,Bruce L. Dalkin,W. Bedford Waters,Michael T. Macfarlane,Paula C. Southwick +12 more
TL;DR: In this paper, a prospective clinical trial at 6 university centers of 6,630 male volunteers 50 years old or older who underwent PSA determination (Hybritech Tandom-E or Tandem-R assays) and digital rectal examination was conducted.
Journal ArticleDOI
Selection of Optimal Prostate Specific Antigen Cutoffs for Early Detection of Prostate Cancer: Receiver Operating Characteristic Curves
William J. Catalona,M'liss A. Hudson,Peter T. Scardino,Jerome P. Richie,Frederick R. Ahmann,Robert C. Flanigan,Jean B. deKernion,Timothy L. Ratliff,Louis R. Kavoussi,Bruce L. Dalkin,W.B. Waters,Michael T. Macfarlane,Paula C. Southwick +12 more
TL;DR: A prospective clinical trial of prostate cancer screening was conducted at 6 university centers including 6,630 men 50 years old or older who underwent a serum prostate specific antigen (PSA) determination and digital rectal examination, which concluded that a serum PSA concentration of 4.0 ng./ml should be used as a general guideline for biopsy in all age groups.
Journal ArticleDOI
Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.
William J. Catalona,Jerome P. Richie,Jean B. deKernion,Frederick R. Ahmann,Timothy L. Ratliff,Bruce L. Dalkin,Louis R. Kavoussi,Michael T. Macfarlane,Paula C. Southwick +8 more
TL;DR: A prospective multicenter clinical trial of nearly 5,000 men in which prostate specific antigen (PSA) density was compared to the serum PSA concentration alone for early detection of prostate cancer concludes that in men with a PSA level of 4.1 to 9.9 ng./ml, a relationship does exist among transrectal ultrasound volume, PSA and positive predictive value for cancer.
Journal ArticleDOI
Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination
Jerome P. Richie,William J. Catalona,Frederick R. Ahmann,M'Liss A. Hudson,Peter T. Scardino,Robert C. Flanigan,Jean B. deKernion,Timothy L. Ratliff,Louis R. Kavoussi,Bruce L. Dalkin,W. Bedford Waters,Michael T. Macfarlane,Paula C. Southwick +12 more
TL;DR: The use of both tests in combination provided the highest rate of detection in all age groups, and younger men have the longest projected life expectancy and, therefore, the most to gain from early prostate cancer detection.
Journal ArticleDOI
The Clinical Usefulness of Serum Prostate Specific Antigen After Hormonal Therapy of Metastatic Prostate Cancer
TL;DR: Following serial PSA levels in patients treated with androgen ablation for metastatic prostate cancer can aid in distinguishing favorable from nonfavorable responders early in the course of therapy and greatly assist in monitoring for progression.